AbbVie Inc (ABBV)

71.51
0.24 0.33
NYSE : Health Care
Prev Close 71.75
Open 71.29
Day Low/High 71.27 / 71.90
52 Wk Low/High 55.06 / 75.04
Volume 3.07M
Avg Volume 5.25M
Exchange NYSE
Shares Outstanding 1.59B
Market Cap 112.70B
EPS 3.60
P/E Ratio 13.44
Div & Yield 2.56 (3.60%)

Latest News

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Evercore ISI analyst Josh Schimmer is bullish on biotech.

Activision Blizzard, EPR Properties, AbbVie: 'Mad Money' Lightning Round

Activision Blizzard, EPR Properties, AbbVie: 'Mad Money' Lightning Round

Jim Cramer is bullish on EPR Properties, Activision Blizzard, AbbVie, and ON Semiconductor.

How Much Cash Do You Have on You?: Cramer's 'Mad Money' Recap (Monday 8/14/17)

How Much Cash Do You Have on You?: Cramer's 'Mad Money' Recap (Monday 8/14/17)

Cramer says this is not the end of the selloff. That's why you should be mentally and financially ready for panic moves -- and opportunities.

AbbVie Receives U.S. FDA Approval Of MAVYRET™ (glecaprevir/pibrentasvir) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT 1-6) In As Short As 8 Weeks

AbbVie Receives U.S. FDA Approval Of MAVYRET™ (glecaprevir/pibrentasvir) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT 1-6) In As Short As 8 Weeks

- MAVYRET is a new 8-week, pan-genotypic treatment for hepatitis C patients without cirrhosis and who are new to treatment

These Stocks Are Ready to Reverse Course

These Stocks Are Ready to Reverse Course

This week's bullish and bearish reversal patterns.

European Commission Grants AbbVie's MAVIRET® (glecaprevir/pibrentasvir) Marketing Authorization For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)

European Commission Grants AbbVie's MAVIRET® (glecaprevir/pibrentasvir) Marketing Authorization For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)

- MAVIRET is a new 8-week, pan-genotypic treatment for hepatitis C patients without cirrhosis and who are new to treatment*

I Believe 'Ugly' Would Be the Proper Term for the Selloff: Market Recon

I Believe 'Ugly' Would Be the Proper Term for the Selloff: Market Recon

What differentiated traders who were injured yesterday from those able to whether a sudden storm? Diversification.

Amazon Falls, Obamacare Repeal Fails - 5 Things You Must Know Before the Market Opens

Amazon Falls, Obamacare Repeal Fails - 5 Things You Must Know Before the Market Opens

U.S. stock futures fall as earnings from Amazon.com disappoint.

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

Wall Street's first glimpse at the second quarter.

AbbVie Receives CHMP Positive Opinion For HUMIRA® (adalimumab) For The Treatment Of Pediatric Patients With Chronic Non-infectious Anterior Uveitis

AbbVie Receives CHMP Positive Opinion For HUMIRA® (adalimumab) For The Treatment Of Pediatric Patients With Chronic Non-infectious Anterior Uveitis

- If approved, HUMIRA® will be the first biologic treatment option in the European Union for pediatric patients with chronic non-infectious anterior uveitis who have had inadequate response to conventional therapy

AbbVie Reaches All-Time Highs

AbbVie Reaches All-Time Highs

Today's breakout could carry the stock sharply higher.

Vertex Growth Expected to Continue with Life-Changing Cystic Fibrosis Treatment

Vertex Growth Expected to Continue with Life-Changing Cystic Fibrosis Treatment

Remarkable data was released from Vertex's triple regiment combination trials.

All That Rises Is Not Tech: Top Takeaways From Jim Cramer's 'Off the Charts'

All That Rises Is Not Tech: Top Takeaways From Jim Cramer's 'Off the Charts'

Tech companies aren't the only ones seeing their shares rise this year.

Investors Should Ignore Washington: Cramer's 'Mad Money' Recap (Tuesday 7/18/17)

Investors Should Ignore Washington: Cramer's 'Mad Money' Recap (Tuesday 7/18/17)

Investors need to focus on earnings and not be distracted by the circus in Washington, Jim Cramer says.

10 Sectors That Will Profit Big-Time From Oil's Crash

10 Sectors That Will Profit Big-Time From Oil's Crash

Oil prices are tumbling down. Bad news for companies and petro states, but great news at the pump and for these ten industries...

Valeant Suffers Another Blow After the Approval of Johnson & Johnson's Psoriasis Treatment

Valeant Suffers Another Blow After the Approval of Johnson & Johnson's Psoriasis Treatment

The approval of Johnson & Johnson's psoriasis treatment will have an adverse impact on Valeant in the second half of 2017, Wells Fargo argued.

What Apple, Microsoft and Some of the World's Biggest Tech Companies Are Doing Now in Healthcare

What Apple, Microsoft and Some of the World's Biggest Tech Companies Are Doing Now in Healthcare

Players include Apple, Google, Microsoft and Samsung.

Samsung Could Sell More Drugs

Samsung Could Sell More Drugs

Samsung's Bioepis unit seeks final approval in Europe of a rheumatoid arthritis drug to compete with Humira.

Who's Afraid of the Amazon Empire?: Cramer's 'Mad Money' Recap (Thursday 6/22/17)

Who's Afraid of the Amazon Empire?: Cramer's 'Mad Money' Recap (Thursday 6/22/17)

Jim Cramer doesn't buy the backlash against Amazon. He says Prime is a very powerful tool and an irresistible bargain.

AbbVie Receives CHMP Positive Opinion For MAVIRET™ (glecaprevir/pibrentasvir) For The Treatment Of Chronic Hepatitis C In All Major Genotypes (GT1-6)

- If approved, MAVIRET™ will provide a shorter, 8-week, pan-genotypic (GT1-6), once-daily option for the majority of people living with the hepatitis C virus (HCV)(1)*

Citigroup, Zoetis, AbbVie, Mattel, Valeant Pharmaceuticals 'Mad Money' Lightning Round

Citigroup, Zoetis, AbbVie, Mattel, Valeant Pharmaceuticals 'Mad Money' Lightning Round

Jim Cramer is bullish on Citigroup, Zoetis, Idexx Labs, AbbVie, Nucor, and Alexion.

AbbVie Declares Quarterly Dividend

Dems Roast Trump for Leaving Medicare Out of Drug Price Order

Dems Roast Trump for Leaving Medicare Out of Drug Price Order

The main thrust of the order appears to be easing regulatory hurdles to drug approvals, which could lower the cost of bringing new treatments to market and thus lower prices.

Epizyme's Positive Cancer Drug Results Likely to Catch the Eye of Celgene, J&J

Epizyme's Positive Cancer Drug Results Likely to Catch the Eye of Celgene, J&J

Epizyme sank almost 20% since their last earnings report, but recent developments show positive data from one of its keynote drugs, Tazemetostat